Room: AAPM ePoster Library
Purpose: The objective of this study was to characterize the performance of the LEP 300 kilovoltage (kV) therapy equipment. The LEP 300 was developed by medical physicists, physician, researchers, engineers and AURA CARE Company. It is a radiotherapy equipment for animals such as mice, dogs and cats. We proceeded the acceptance test and beam data commissioning to determine and confirm the characteristics of the equipment and beam.
Methods: We investigated the mechanical functionality, alignment and interlocks and so on. For beam characteristics, we assessed output, dose linearity and reproducibility, beam flatness and symmetry, percent depth dose (PDD), and half-value layer (HVL). We used a water-equivalent solid phantom, Garchromic EBT3 film and ion chamber. All measurements were input to "CorePlan" radiation treatment planning (RTP) system and then compared with measured data and calculated data.
Results: Most of the measured values were within the tolerances of linac given by Varian. The symmetry results of the whole depth were within 1.1% in crossline and inline direction(10x10 cm²field). The flatness was 3.6% in crossline, 4.3% in inline direction. Half-value layer was 2.25 mmCu. The output of the beam was 1.295 Gy/min at 2cm depth. The result of comparing RTP System and measured data, the difference of PDD data was within 3.8%. And the difference of profile data was within 1% (10x10 cm²field, 5 mm depth).
Conclusion: this study, we confirmed the mechanical accuracy and uniformity of the dose distribution of the 300 kV animal radiotherapy equipment. However, in the 10x10 cm²field profile, the difference of profile with RTP system at the tail was occurred. If we find the cause of the difference, we expected beam data could be used for standard for LEP 300.
Funding Support, Disclosures, and Conflict of Interest: This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF- 2018R1D1A1B07050217).